Rznomics Inc.
PublicRznomics Inc. is now publicly traded
The data on this page reflects Rznomics Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
VC Round
Dec 23, 2023
Est. Valuation at Exit
$100.07M
Total Funding Raised
$55.59M
Company Overview
Rznomics Inc. is a clinical-stage biopharmaceutical company that develops RNA-based gene therapies for cancers and intractable diseases using its proprietary trans-splicing ribozyme platform.
AI Layer
Non-AI
Keywords
Rznomics Inc. Comparables
Compare Rznomics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| エディットフォース株式会社 | 76% | |
| Ethonova | 63% | |
| Sotirion Biosciences | 51% |
Rznomics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 23, 2023 | ||||
| Series C | Jun 7, 2022 | ||||
| Series A | Sep 20, 2019 |
Rznomics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shinhan Venture Investment | Series C |
| UTC Investment | Series C |
| KB Investment | VC Round |
| Synergy IB Investment | Series A |
| QUAD Investment Management | Series A |
| IBK Capital | Series C |
| LSK Investment | Series A |
Recent news
Latest coverage and updates
- is_developingAug 25, 2026
Rznomics is developing RNA-based gene therapies on Aug 25th '26.
- partners_withAug 24, 2026
Rznomics partnered with Lilly Group on Aug 23rd '26.
Rznomics Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access